Developing Aptamers by Cell-Based SELEX
Developing Aptamers by Cell-Based SELEX
复制标题
DOI：
10.1007/978-1-4939-3197-2_3
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
de Franciscis, Vittorio
中科院分区：
文献类型：
--
作者：
Catuogno, Silvia;Esposito, Carla Lucia;de Franciscis, Vittorio
可靠地靶向细胞表面疾病相关蛋白是化学生物学和分子医学中的一个重大挑战。在这方面，适体代表了一类非常有吸引力和创新的配体分子。适体是通过重复的体外程序生成的，称为SELEX（指数富集配体系统进化）。为了产生用于高度修饰的细胞表面结合蛋白和跨膜受体的适体，最近已将SELEX程序调整为使用活细胞作为复杂靶标（称为“cell-SELEX”）。在这里，我们概述了cell-SELEX技术领域的最新进展，提供了我们实验室开发的用于鉴定人类恶性胶质瘤和非小细胞胶质瘤的特异性标记的差异细胞-SELEX方法的详细描述，细胞肺癌还将描述用于评价结合特异性和用于初步鉴定潜在靶受体的程序。
The reliable targeting of cell surface disease-associated proteins is a major challenge in chemical biology and molecular medicine. In this regard, aptamers represent a very attractive and innovative class of ligand molecules. Aptamers are generated by a reiterated in vitro procedure, named SELEX (Systematic Evolution of Ligands by Exponential enrichment). In order to generate aptamers for heavily modified cell surface-bound proteins and transmembrane receptors, the SELEX procedure has been recently adapted to the use of living cells as complex targets (referred as "cell-SELEX").Here we give an overview on the most recent advances in the field of cell-SELEX technology, providing a detailed description of the differential cell-SELEX approach that has been developed in our laboratory to identify specific signatures for human malignant glioma and non-small-cell lung cancer. The procedures used for the evaluation of binding specificity and for the preliminary identification of potential target receptors will be also described.